Effect on Survival of Longer Intervals Between Confirmed Diagnosis and Treatment Initiation Among Low-Income Women With Breast Cancer

John M. McLaughlin(Pfizer (United States)), Electra D. Paskett(The Ohio State University), Rajesh Balkrishnan(Penn State Milton S. Hershey Medical Center), Roger T. Anderson(Virginia Commonwealth University), Amy K. Ferketich(The Ohio State University), Eric E. Seiber(Penn State Milton S. Hershey Medical Center)

Journal of Clinical Oncology

November 20, 2012

10.1200/jco.2012.39.7695

Cited by 211

Related Papers

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

|The Lancet|2021|1.7k

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

|The Lancet|2021|1.3k

Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer

|JAMA Oncology|2016|721

Approaching Health Disparities From a Population Perspective: The National Institutes of Health Centers for Population Health and Health Disparities

|American Journal of Public Health|2008|565

Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials

|JAMA|2020|412